Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in functional mitral regurgitation
NCT05849766Phase 3Completed
- Sponsor
- October 6 University
- Start
- Apr 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in dilated cardiomyopathy (DCM) (2 arms), sponsored by October 6 University. Primary endpoint: Effective Regurgitant Orifice Area at 6 months. Started Apr 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT05849766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849766.